WO2003016559A3 - Method for treating diabetes based on the modulation of nh4alpha gene expression - Google Patents
Method for treating diabetes based on the modulation of nh4alpha gene expression Download PDFInfo
- Publication number
- WO2003016559A3 WO2003016559A3 PCT/DK2002/000537 DK0200537W WO03016559A3 WO 2003016559 A3 WO2003016559 A3 WO 2003016559A3 DK 0200537 W DK0200537 W DK 0200537W WO 03016559 A3 WO03016559 A3 WO 03016559A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nh4alpha
- modulation
- hnf4α
- gene expression
- treating diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002325821A AU2002325821A1 (en) | 2001-08-17 | 2002-08-15 | Method for treating diabetes based on the modulation of nh4alpha gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01610085.1 | 2001-08-17 | ||
EP01610085 | 2001-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003016559A2 WO2003016559A2 (en) | 2003-02-27 |
WO2003016559A3 true WO2003016559A3 (en) | 2003-10-16 |
Family
ID=8183557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2002/000537 WO2003016559A2 (en) | 2001-08-17 | 2002-08-15 | Method for treating diabetes based on the modulation of nh4alpha gene expression |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002325821A1 (en) |
WO (1) | WO2003016559A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006008008A2 (en) * | 2004-07-23 | 2006-01-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a) |
EP1712641A1 (en) * | 2005-04-14 | 2006-10-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of novel HNF4a target genes and their gene products |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187533B1 (en) * | 1996-09-10 | 2001-02-13 | Arch Development Corporation | Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α |
-
2002
- 2002-08-15 WO PCT/DK2002/000537 patent/WO2003016559A2/en not_active Application Discontinuation
- 2002-08-15 AU AU2002325821A patent/AU2002325821A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187533B1 (en) * | 1996-09-10 | 2001-02-13 | Arch Development Corporation | Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α |
Non-Patent Citations (5)
Title |
---|
DATABASE EMBL 10 September 1999 (1999-09-10), XP002192981 * |
FURUTA HIROTO ET AL: "Organization and partial sequence of the hepatocyte nuclear factor-4-alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY.", DIABETES, vol. 46, no. 10, 1997, pages 1652 - 1657, XP001064298, ISSN: 0012-1797 * |
LAUSEN JOERN ET AL: "Naturally occurring mutations in the human HNF4alpha gene impair the function of the transcription factor to a varying degree.", NUCLEIC ACIDS RESEARCH., vol. 28, no. 2, 15 January 2000 (2000-01-15), pages 430 - 437, XP002192980, ISSN: 0305-1048 * |
MOLLER ANN M ET AL: "A novel Phe75fsdelT mutation in the hepatocyte nuclear factor-4alpha gene in a Danish pedigree with maturity-onset diabetes of the young.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 1, January 1999 (1999-01-01), pages 367 - 369, XP001064367, ISSN: 0021-972X * |
NAKHEI HASSAN ET AL: "An alternative splice variant of the tissue specific transcription factor HNF4alpha predominates in undifferentiated murine cell types.", NUCLEIC ACIDS RESEARCH, vol. 26, no. 2, 15 January 1998 (1998-01-15), pages 497 - 504, XP002192978, ISSN: 0305-1048 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002325821A1 (en) | 2003-03-03 |
WO2003016559A2 (en) | 2003-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE320500T1 (en) | NUCLEOTIDE SEQUENCES FOR CONTROLLING THE EXPRESSION OF DNA SEQUENCES IN A CELLULAR HOST | |
AU2733895A (en) | A fungus wherein the area gene has been modified and an area gene from aspergillus oryzae | |
PL1824977T3 (en) | Promoter nucleic acid derived from Corynebacterium genus , expression cassette comprising the promoter and vector , host cell comprising the vector , vector and method for expressing a gene using the cell . | |
HK1029142A1 (en) | Characterisation of gene function using double stranded rna inhibition | |
WO2003027266A3 (en) | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof | |
WO2004101759A3 (en) | Novel lipolytic enzyme lip2 | |
WO2004101760A3 (en) | Novel lipolytic enzyme elip | |
WO2001036641A3 (en) | DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO | |
WO2000061622A3 (en) | Genes associated with diseases of the kidney | |
WO2002094997A3 (en) | Transcriptional regulation of target genes | |
EP0892048A3 (en) | XAF genes and polypeptides and their use for modulating apoptosis | |
WO2003004628A3 (en) | Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme | |
WO2003004681A3 (en) | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon | |
WO2002012470A3 (en) | A member of the lysyl oxidase gene family | |
WO2003016559A3 (en) | Method for treating diabetes based on the modulation of nh4alpha gene expression | |
WO2004074448A3 (en) | mTOR KINASE-ASSOCIATED PROTEINS | |
WO2001016317A3 (en) | Polycyclic aromatic hydrocarbon induced molecules | |
AU1727597A (en) | Purified sr-p70 protein | |
WO2001088124A3 (en) | Method and reagent for the inhibition of erg | |
WO2003020887A3 (en) | Gene identification | |
WO1997020928A1 (en) | Novel semaphorin z and gene encoding the same | |
EP0897011A3 (en) | Novel arginine deiminase | |
WO2003033692A3 (en) | Use of the adenoviral e2 late promoter | |
EP1908835A3 (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
ATE219515T1 (en) | METHODS AND REAGENTS FOR REGULATING APOPTOSIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |